तंबाकू और धूम्रपान और टोफासिटिनिब का इंटरैक्शन

Patients who are current or past smokers are at additional increased risk.

Patients who are current or past smokers are at additional increased risk [see Clinical Studies (14.6) ].

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with XELJANZ/XELJANZ XR, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy while on treatment, and patients who are current or past smokers.

The incidence rate of lung cancers per 100 patient-years among current and past smokers was 0.59 for XELJANZ tablets 10 mg twice a day, 0.48 for XELJANZ tablets 5 mg twice a day, and 0.27 for TNF blockers [see Clinical Studies (14.6) ] .